Series of setbacks have not caused Orphazyme CEO to consider departing

Even though much has happened in the four months in which Christophe Bourdon has sat in the main seat at Orphazyme, the newly-minted CEO is determined to seek opportunities in NPC. He does not have a lot to say on where he sees himself in a year.
Orphazyme CEO Christophe Bourdon | Photo: Orphazyme / PR
Orphazyme CEO Christophe Bourdon | Photo: Orphazyme / PR
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

A lot has happened since Christophe Bourdon was appointed the head of Orphazyme back in early March. In spite of a series of consecutive disappointments, the CEO does not plan to seek other opportunities than the one he currently has as the chief of the Copenhagen-based biotech company, he tells MedWatch.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading